Clinical Trial Update: Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study [NA]

View source ↗

Summary

A clinical trial evaluating mesothelin-targeted CAR-T cells as neoadjuvant therapy for resectable pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Mesothelin-targeted CAR-T cells (CAR-T cells targeting mesothelin)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Pancreatic Cancer | NA | Status: WITHDRAWN